Open AccessResource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA
Author(s) -
Yit Yang,
Louise Downey,
Hemal Mehta,
Bushra Mushtaq,
Niro Narendran,
Nirmal Patel,
Praveen J. Patel,
Filis Ayan,
Kara Gibson,
Franklin Igwe,
Pete Jeffery
Publication year - 2017
Publication title -
ophthalmology and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.189
H-Index - 17
eISSN - 2193-6528
pISSN - 2193-8245
DOI - 10.1007/s40123-017-0091-9
Subject(s) - medicine , ranibizumab , pro re nata , macular degeneration , regimen , interim , visual acuity , interim analysis , ophthalmology , cohort , confidence interval , retrospective cohort study , clinical trial , bevacizumab , surgery , pediatrics , chemotherapy , history , archaeology
Ranibizumab is an inhibitor of vascular endothelial growth factor-A (anti-VEGF) approved for the treatment of neovascular age-related macular degeneration (nAMD). The treat and extend (T&E) regimen can potentially reduce the burden of clinic visits compared with a pro re nata (PRN) regimen. Retrospective, interim analyses of clinical effectiveness, treatment and resource use patterns were conducted using real-world data in England and Wales from the TERRA study.